ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ANL / forecast
OLMA (29) ZVRA (37) BCAX (30) NVCT (37) ⌘ Pro Terminal →

Adlai Nortye Group Ltd. (ANL) 12-Month Stock Forecast & Price Target Cone

$9.37 -1.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.32

Adlai Nortye Group Ltd. (ANL) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $615.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ANL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ANL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Adlai Nortye Group Ltd. (NASDAQ: ANL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $9.37 (-1.88% 1D, market cap $615.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ANL ranks #329 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ANL compare to OLMA and ZVRA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANL carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OLMA (Olema Pharmaceuticals Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -32.8%, cap $612.5M) and ZVRA (Zevra Therapeutics Inc.) posts a D- grade (37/100 RQD, P/E 7.4x, ROIC -32.3%, cap $610.5M). Among the 5-stock peer group, ZVRA leads on earnings multiple (7.4x) while ZVRA leads on capital efficiency (-32.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ANL?
▼

For Adlai Nortye Group Ltd. (ANL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #329 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.32 (-0.53%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (12)Whales (4)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
$18 Bull$9 Base$7 Bear
📬 FREE ANL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY ANL SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($17.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$11.76-9.5% Next Q
Q2 (-2Q)
51
Grade C-$10.64+0.7% Next Q
Q3 (-1Q)
49
Grade D$10.71-12.5% Next Q
Current
46
Grade D$9.37-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ANL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ANL currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.66) and Max Pain ($9.84) forces dealer call-delta covering toward $18.11.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ANL Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ANL Position Size: $10,000

Shares at $9.37: 1067.2 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $6.91
$7,375
$-2,625 (-26.3%)
12M Consensus BaseTarget $8.86
$9,456
$-544 (-5.4%)
12M Bull Case BreakoutTarget $18.11
$19,328
+$9,328 (+93.3%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$974%A
Goldman SachsSector Coverage LeadUNDERPERFORM$1769%B
JP MorganUS Large-Cap ResearchSELL$858%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANL)

  • ✓Walkthrough of ANL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ANL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -37.41%🛡️ HOLDING TREND SUPPORT
2026-11-03O $10.28H $10.28L $9.37C $9.37VOL 262.1K
RES: $18.37SUP: $9.38SMA50: $13.66SMA200: $11.47
$17.82$14.20$10.59$6.97$3.35RES $18.37SUP $9.38$9.372026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANL Butterfly Map → + Track ANL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ANL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ANL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANL)

Health Care Rank #329 of 1015 ⚔️ OLMA vs ANL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANL vs. OLMA, ZVRA, BCAX, NVCT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Adlai Nortye Group Ltd. (ANL) ranks #329 by composite RQD confidence (46/100, grade D) and #410 by equity capitalization ($615.0M). Within this direct 5-issuer industry benchmark cohort, ZVRA leads on earnings valuation at 7.4x trailing P/E, while ZVRA leads on capital efficiency and profitability with -32.3% ROIC and — gross margin. ANL currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ANL ACTIVE
Adlai Nortye Group Ltd.
D 46/100 — — — -1.88% $615.0M Benchmark Subject
OLMA
Olema Pharmaceuticals Inc.
E 29/100 — — -32.8% +1.00% $612.5M /olma-vs-anl →
ZVRA
Zevra Therapeutics Inc.
D- 37/100 7.4x — -32.3% -1.75% $610.5M /zvra-vs-anl →
BCAX
Bicara Therapeutics Inc.
E 30/100 — — -35.0% -13.14% $604.2M /bcax-vs-anl →
NVCT
Nuvectis Pharma Inc.
D- 37/100 — — -35.0% +3.79% $602.7M /nvct-vs-anl →

2. ANL Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Adlai Nortye Group Ltd. (ANL) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $615.0M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ANL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Adlai Nortye Group Ltd. (NASDAQ: ANL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $9.37 (-1.88% 1D, market cap $615.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ANL ranks #329 in composite RQD confidence.

How does ANL compare to OLMA and ZVRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANL carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OLMA (Olema Pharmaceuticals Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -32.8%, cap $612.5M) and ZVRA (Zevra Therapeutics Inc.) posts a D- grade (37/100 RQD, P/E 7.4x, ROIC -32.3%, cap $610.5M). Among the 5-stock peer group, ZVRA leads on earnings multiple (7.4x) while ZVRA leads on capital efficiency (-32.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANL?

For Adlai Nortye Group Ltd. (ANL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #329 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANL trading relative to its 50-day, 200-day, and 52-week technical levels?

ANL last traded at $9.37 (-1.88% on volume of 272,633 shares), positioning the stock -31.41% below its 50-day simple moving average ($13.66) and -18.31% below its 200-day simple moving average ($11.47). Across its 52-week range of $0.88 to $17.25, ANL sits at the 51.9% percentile with a 14-day RSI of 34.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.20 to $10.54).

Direct Sub-Reports: ANL RQD Cockpit ANL 12M Forecast ANL Earnings & Move ANL Dividends & DRIP ANL Insiders & 13F ANL Whale Options ANL Profit Sankey ANL News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

ANL — Adlai Nortye Group Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Adlai Nortye Group Ltd. (ANL) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $9.37 (-1.88% 1D, market capitalization $615.0M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (ANL) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, with a market capitalization of $0.7B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 4/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $0.88 – $17.25 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream supply-chain dependencies, sector correlations, or proprietary signal links are recorded (supply_chain: NONE; butterfly_links: empty; proprietary_signals: empty). Second-order bottlenecks cannot be identified from the source data. The one development in the news feed that implies a partnership (the Lilly and Merck drug supply arrangement for a combination trial) is not mapped in the graph and should be treated as an unmapped dependency rather than a confirmed supply-chain link.

  • Key Question #1: Can ANL sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $17.25 52-week high?
  • Key Question #3: How sensitive is ANL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ANL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Adlai Nortye Group Ltd. (ANL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ANL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ANL Bull vs. Bear Conversation Board — What's Your Call at $9.37?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ANL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $12.22 (+28.0%)
📌 Pinned Debate

Balance sheet holds up best of the five pillars (Forensic 13/20 with Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) while the stock tr

Picked up a starter position in ANL in my $100K Virtual Cash book at $9.55. Balance sheet holds up best of the five pillars (Forensic 13/20 with Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) while the stock trades in a wide 52-week range up to $17.25.. Trading inside a $1.72–$17.25 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

SectorRotator 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $7.83 (-18.0%)
Spot @ $9.55

Zero ROIC and zero FCF yield, weak whale 13F flow (5/20), and a Distribution Warning verdict point to no cash-based support for the sto

Fading this rally in ANL at $9.55. Zero ROIC and zero FCF yield, weak whale 13F flow (5/20), and a Distribution Warning verdict point to no cash-based support for the stock.. With a beta of 1.0 and the stock sitting at $9.55 (52-wk range $1.72–$17.25), the easy multiple expansion is already priced in.

LIVE TAPE